Literature DB >> 7330599

Serum inhibitory factor in lepromatous leprosy: its effect on the pre-S-phase cell-cycle kinetics of mitogen-stimulated normal human lymphocytes.

R C Potts, M M Sherif, A J Robertson, J H Gibbs, R A Brown, J S Beck.   

Abstract

The sera of ten Egyptian man with long-standing lepromatous leprosy (LL) (mean duration 17.4 years) that had failed to respond to dapsone treatment were shown to inhibit mitogen stimulation responses of normal human lymphocytes. When first tested, the sera partly inhibited the response to phytohaemagglutinin (PHA) and pokeweed mitogen and virtually abolished that to concanavalin A (Con A): after repeated freezing and thawing, the Con A inhibition had disappeared, whereas the PHA response was still partly inhibited. The inhibitory serum factor(s) had similar actions on lymphocytes from each of six normal donors. Although the sera varied in potency, they showed similar dose-response curves when tested against lymphocytes from a single donor. The principal action of the sera was to reduce the number of cells responding to mitogen, without modifying the kinetics of recruitment or rate of volume growth during G1-phase in those cells that were unaffected by the inhibitory substances(s). Study of PHA dose-response curves and of the effect of delayed addition of LL serum suggested that the serum factor(s) act by diminishing the responsiveness of the cells, rather than by reducing the concentrations of free mitogen or by blocking cell membrane mitogen receptors. The serum from one apparently healthy attendant, who had nursed leprosy patients for 30 years but who did not have leprosy or other chronic infective disease, inhibited completely stimulation by all three mitogens in a manner different from that of LL sera. Serum from the other 13 control patients did not modify the response of normal lymphocytes to stimulation by any of the three mitogens studied. It was concluded that the inhibitory factor(s) in the serum of patients with LL were a consequence of the disease and not of the environment in which the patients lived. Microscopy confirmed that the techniques used for recovery of the cultured cells did not introduce bias into the volume spectroscopy measurements.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7330599     DOI: 10.1111/j.1365-3083.1981.tb00564.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  6 in total

1.  Mitogen stimulation of peripheral blood lymphocytes of duodenal ulcer patients during treatment with cimetidine or ranitidine.

Authors:  N R Peden; A J Robertson; E J Boyd; R A Brown; J H Gibbs; R C Potts; K G Wormsley; J S Beck
Journal:  Gut       Date:  1982-05       Impact factor: 23.059

2.  Some tetracycline drugs suppress mitogen-stimulated lymphocyte growth but others do not.

Authors:  R C Potts; A MacConnachie; R A Brown; J H Gibbs; A J Robertson; H A Hassan; J S Beck
Journal:  Br J Clin Pharmacol       Date:  1983-08       Impact factor: 4.335

3.  Cytogenetic studies in leprosy patients before and after chemotherapy.

Authors:  D D'Souza; B C Das; I M Thomas
Journal:  Hum Genet       Date:  1991-10       Impact factor: 4.132

4.  Characterization of a factor in leprosy serum that inhibits the growth of mitogen-stimulated normal human lymphocytes.

Authors:  M A Kerr; Y M Hussein; R C Potts; J S Beck; M M Sheriff
Journal:  Immunology       Date:  1987-06       Impact factor: 7.397

5.  In vitro effects of doxycycline and tetracycline on mitogen stimulated lymphocyte growth.

Authors:  R C Potts; H A Hassan; R A Brown; A MacConnachie; J H Gibbs; A J Robertson; J S Beck
Journal:  Clin Exp Immunol       Date:  1983-08       Impact factor: 4.330

6.  The mechanism of action of the factor in leprosy serum that inhibits the growth of mitogen-stimulated normal human lymphocytes.

Authors:  Y M Hussein; M A Kerr; J S Beck
Journal:  Immunology       Date:  1987-06       Impact factor: 7.397

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.